MedPath

NATIONAL INSTITUTES OF HEALTH

NATIONAL INSTITUTES OF HEALTH logo
🇺🇸United States
Ownership
Subsidiary, Private
Established
1948-01-01
Employees
1K
Market Cap
-
Website
http://www.nidcr.nih.gov

Clinical Trials

4.0k

Active:433
Completed:2546

Trial Phases

6 Phases

Early Phase 1:23
Phase 1:1278
Phase 2:1656
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3400 trials with phase data)• Click on a phase to view related trials

Phase 2
1656 (48.7%)
Phase 1
1278 (37.6%)
Phase 3
258 (7.6%)
Not Applicable
168 (4.9%)
Early Phase 1
23 (0.7%)
Phase 4
17 (0.5%)

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Not Applicable
Not yet recruiting
Conditions
Relapsed and/or Refractory Mature T Cell Malignancy
Peripheral T-Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
Monomorphic Epithelialtropic Intestinal Lymphoma
Enteropathy Associated T-cell Lymphoma
Cutaneous T-Cell Lymphoma
Mycosis Fungoides
Subacute Panniculitis-like T-cell Lymphoma
Interventions
Biological: Autologous CCR4 CAR T cells
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT07055477
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Not Applicable
Not yet recruiting
Conditions
Locally Recurrent Skin Squamous Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
Interventions
Drug: Amivantamab and Recombinant Human Hyaluronidase
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
First Posted Date
2025-06-29
Last Posted Date
2025-07-08
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
86
Registration Number
NCT07042295

Exploring How to Adapt an Evidence-Based Mindful Self-Compassion Program for Young Adults With Li-Fraumeni Syndrome

Recruiting
Conditions
Li-Fraumeni Syndrome
First Posted Date
2025-06-24
Last Posted Date
2025-06-29
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
20
Registration Number
NCT07032922
Locations
🇺🇸

NCI Shady Grove Campus, Rockville, Maryland, United States

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Not yet recruiting
Conditions
Germline Mutation
Myelodysplastic Syndromes
Acute Myeloid Leukemia
First Posted Date
2025-06-13
Last Posted Date
2025-07-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
510
Registration Number
NCT07019155
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

Phase 1
Not yet recruiting
Conditions
Acute Myeloid Leukemia Post Cytotoxic Therapy
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Interventions
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Procedure: Imaging Procedure
Procedure: Lumbar Puncture
First Posted Date
2025-06-10
Last Posted Date
2025-06-10
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
47
Registration Number
NCT07012044
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 807
  • Next

News

MIT Develops Implantable Device for Automated Glucagon Delivery to Prevent Diabetic Hypoglycemia

MIT engineers have developed an implantable device that automatically administers glucagon to prevent life-threatening hypoglycemic episodes in diabetics, with testing in mice showing blood sugar stabilization within 10 minutes.

Novel Tiancimycin-Based Antibody-Drug Conjugate Shows Promise Against Aggressive Lymphoma

Scientists at The Herbert Wertheim UF Scripps Institute developed a novel antibody-drug conjugate combining tiancimycin, a natural compound from soil microbes, with a "double-decker" antibody targeting CD79b for diffuse large B cell lymphoma treatment.

UCLA Researchers Receive $3.5 Million NIH Grant to Develop Novel Mpox Antivirals Targeting Immune Evasion

UCLA-led researchers received a $3.5 million NIH grant to develop treatments for mpox, focusing on a more virulent strain causing increased deaths among children in the Democratic Republic of Congo.

India Launches First Indigenous Dengue Vaccine Phase 3 Trial with Over 10,000 Participants

The Indian Council of Medical Research (ICMR) and Panacea Biotec have initiated India's first Phase 3 clinical trial for an indigenous tetravalent dengue vaccine called DengiAll.

Quiver Bioscience Secures $2.15M NIH Grant to Develop AI-Powered CNS Drug Safety Platform

Quiver Bioscience received a $2.15 million Phase II SBIR grant from the National Institute of Neurological Disease and Stroke to develop an integrated platform for predicting safety of CNS-targeted antisense oligonucleotide therapeutics.

AN2 Therapeutics Completes 200-Patient Study Revealing 40% Mortality Rate in Acute Melioidosis

AN2 Therapeutics completed a 200-patient observational study in acute melioidosis, revealing a striking mortality rate of nearly 40% by Day 90 despite standard of care treatment.

KU Medical Center Receives $31 Million NIH Grant to Expand Pediatric Clinical Trial Access in Underserved Areas

The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history.

Oxford Scientists Develop Single-Shot Malaria Vaccine Using Programmable Microcapsule Technology

University of Oxford researchers have developed a programmable microcapsule delivery system that enables complete malaria vaccination in a single injection, eliminating the need for booster visits.

TAM Global Appoints Leading Cancer Immunologist Dr. Francesco Marincola as Chief Scientific Officer

TAM Global has appointed Dr. Francesco Marincola, one of the world's most prolific tumor immunologists with over 700 peer-reviewed publications, as Chief Scientific Officer across its expanding healthcare platform.

University of Wisconsin Researchers Develop Personalized Cancer Vaccines Using Pyroptotic Vesicles to Prevent Tumor Recurrence

University of Wisconsin-Madison researchers have developed personalized cancer vaccines using pyroptotic vesicles, tiny sacs from dying cancer cells, that significantly extended survival in mouse models of triple-negative breast cancer and melanoma.

© Copyright 2025. All Rights Reserved by MedPath